Results 211 to 220 of about 724,876 (319)
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech +4 more
wiley +1 more source
Rake angle optimization for balanced efficiency and durability in PDC cutter cutting granite interaction via infrared thermal dynamics and fragmentation mechanism. [PDF]
He X +5 more
europepmc +1 more source
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner +9 more
wiley +1 more source
Strut and tie model for predicting shear behavior of interior RC beam column joints under seismic loading. [PDF]
Zhao W, Yan Y, Yue Y, Xue R, Yan X.
europepmc +1 more source
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner +14 more
wiley +1 more source
Sex differences in medication discontinuation in axial spondyloarthritis.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall +9 more
wiley +1 more source

